Biogen says Leqembi sales are improving slowly following lackluster launch

Title

Biogen Reports Gradual Uptick in Leqembi Sales After Underwhelming Launch

Leqembi, Biogen's Alzheimer's disease drug co-developed with Eisai, has shown a modest but steady increase in sales since its launch, following an initially lackluster introduction to the market4 3.
In Q1 2025, Leqembi generated $96 million in sales, a significant rise from $19 million in the same quarter of the previous year, with $52 million stemming from the U.S. market4 3.
Leqembi is currently the sole Alzheimer’s drug in Biogen’s portfolio after the company discontinued Aduhelm at the start of 20243.
Biogen and Eisai equally split revenue from Leqembi’s sales3.
New regulatory milestones are expected to help boost sales, including full FDA approval for maintenance dosing in January 2025 and authorization for use in the European Union in April 20253 5.
Although the growth has been steady, analysts describe Leqembi’s commercial performance as "modest," suggesting that while sales are improving, they remain below initial expectations3.
Biogen’s overall Q1 2025 revenue rose 6% year-over-year to $2.4 billion, surpassing estimates, though the main growth drivers were other products as Leqembi’s uptake continues at a gradual pace2 1.
The commercial focus for Biogen remains on increasing Leqembi’s adoption as it aims to solidify its position in the Alzheimer’s treatment space3.